MedTrace Logo

The Effects of Transcranial Magnetic Stimulation on Retina and Choroidal Structures

NCT06615804 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2024-09-27

No results posted yet for this study

Summary

Transcranial Magnetic Stimulation (TMS) therapy is an approved and effective treatment option in treatment-resistant depression. The present study aims to investigate the effect of TMS treatment on eye structures such as retina, macula, and choroid. These patients will be evaluated using the Optic Coherence Tomography (OCT) device, which is routinely used in ophthalmology practice, before and after a month long TMS treatment. The main question it aims to answer is:

* Does TMS treatment influence the structures in eyes. The patients will visit the ophthalmology clinic before and after the TMS treatment.
* TMS treatment will be applied 5 days a week for 4 weeks.

Conditions

  • Major Depressive Disorders

Interventions

BIOLOGICAL

Transcranial Magnetic Stimulation

Transcranial Magnetic Stimulation (TMS) is a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain. It's primarily used to treat depression, especially in patients who haven't responded well to traditional treatments like medications or psychotherapy. The most common target is the dorsolateral prefrontal cortex, a region often underactive in people with depression. The magnetic pulses stimulate or inhibit brain activity in the targeted area. This is believed to help reset or correct patterns of neural activity associated with depression and other psychiatric disorders. TMS represents an alternative for those struggling with depression, offering a non-invasive approach with relatively few side effects and significant potential benefits

Sponsors & Collaborators

  • Western University, Canada

    collaborator OTHER

  • Gulhane Training and Research Hospital

    lead OTHER_GOV

Principal Investigators

  • Beyazit Garip, MD · Gulhane Trainig and Research Hospital

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2023-05-30
Completion
2023-05-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06615804 on ClinicalTrials.gov